암 악액질 시장 : 시장 예측(2026-2032년)

The Cancer Cachexia Market is projected to grow by USD 4.10 billion at a CAGR of 8.14% by 2032.

Cancer Cachexia Executive Summary

Cancer cachexia is a multifactorial metabolic syndrome characterized by involuntary weight loss, skeletal muscle wasting, systemic inflammation, reduced food intake, and impaired functional status in people with cancer. It is most frequently associated with advanced malignancies, particularly pancreatic, gastric, esophageal, lung, colorectal, and head and neck cancers, and is clinically significant because it can reduce treatment tolerance, worsen quality of life, increase hospitalization risk, and contribute to cancer-related mortality. Unlike simple starvation, cancer cachexia cannot be fully reversed by conventional nutritional support alone, making early screening, multimodal intervention, and coordinated oncology care essential. Current clinical practice increasingly emphasizes validated nutritional risk screening, body composition evaluation, symptom management, physical function monitoring, and inflammation-informed care pathways. As oncology moves toward more personalized and supportive treatment models, cancer cachexia is gaining strategic importance across clinical research, drug development, medical nutrition therapy, rehabilitation, palliative care, and digital health-enabled patient monitoring.

Transformative Shifts in the Cancer Cachexia Landscape

The cancer cachexia landscape is shifting from late-stage symptom management toward proactive, multidisciplinary intervention. Historically, cachexia was often recognized only after severe weight loss and functional decline; however, growing clinical awareness is encouraging earlier identification through weight-change tracking, appetite assessment, muscle mass evaluation, and performance-status monitoring. The field is also moving beyond single-modality approaches, as clinical evidence supports integrated care that combines nutritional counseling, anti-inflammatory and metabolic strategies, resistance or endurance exercise where feasible, symptom control, and psychosocial support. Regulatory and clinical research attention is increasing around endpoints such as lean body mass, handgrip strength, physical function, patient-reported outcomes, treatment adherence, and survival-related clinical relevance. At the same time, advances in oncology have extended survival for many cancers, creating greater need to manage chronic complications such as muscle wasting, fatigue, anorexia, and treatment intolerance. The most important transformation is the recognition that cachexia is not merely a terminal event but a clinically actionable syndrome that should be addressed across the cancer care continuum.

Cumulative Impact of Artificial Intelligence on Cancer Cachexia

Artificial intelligence is beginning to influence cancer cachexia through earlier risk detection, longitudinal patient monitoring, imaging-based muscle assessment, and precision supportive care. AI-enabled analysis of electronic health records can identify patterns involving weight loss, reduced albumin, inflammatory markers, treatment intensity, appetite-related symptoms, and hospitalization history to flag patients who may require nutritional or rehabilitation intervention. Computer vision and radiomics applied to routine CT imaging can quantify skeletal muscle area and muscle quality, supporting objective assessment of sarcopenia without requiring additional imaging procedures. Wearables and remote monitoring platforms can add real-time data on mobility, fatigue, sleep, and physical activity, helping clinicians detect functional decline between visits. In clinical research, AI can support patient stratification, endpoint harmonization, trial recruitment, and biomarker discovery across inflammatory, metabolic, endocrine, and microbiome-related pathways. The cumulative impact of artificial intelligence is expected to strengthen precision cachexia care by enabling earlier intervention, individualized treatment planning, and better measurement of clinically meaningful outcomes, provided that data quality, interoperability, bias mitigation, and clinical validation remain central priorities.

Key Regional Insights Across Cancer Cachexia Care

In Asia-Pacific, the burden of cancer cachexia is shaped by high cancer incidence, rapidly aging populations, expanding oncology infrastructure, and wide variation in nutrition support access across urban and rural care settings. Countries with substantial gastrointestinal, lung, and liver cancer burdens face strong clinical need for early cachexia screening and integrated supportive care. North America demonstrates broad adoption of multidisciplinary oncology, palliative care integration, clinical nutrition services, cancer rehabilitation, and digital health tools, supporting more structured identification of weight loss, sarcopenia, and cancer-related functional decline. Latin America is experiencing rising demand for supportive oncology services as cancer diagnosis and treatment access improve, although disparities in specialist availability, nutritional assessment, rehabilitation capacity, and palliative care access continue to influence patient outcomes. Europe benefits from established oncology guidelines, geriatric oncology programs, nutritional care standards, and research networks that support evidence-based cancer cachexia management, particularly in advanced cancer and multimorbidity settings. The Middle East is strengthening cancer care capacity through investment in tertiary oncology centers, survivorship services, specialist training, and palliative care development, creating opportunities to embed cachexia pathways earlier in the treatment journey. Africa faces the dual challenge of late-stage cancer diagnosis and variable access to oncology nutrition, symptom control, rehabilitation, and palliative care, making scalable screening tools, workforce training, and essential supportive-care integration particularly important for improving cachexia-related outcomes.

Key Group Insights for Cancer Cachexia Priorities

Within ASEAN, cancer cachexia priorities are closely linked to expanding access to oncology diagnosis, affordability of supportive care, and the need for standardized nutrition and functional assessment across diverse health systems. The GCC is advancing specialized cancer services and tertiary care capacity, with increasing emphasis on comprehensive oncology models that integrate nutrition, rehabilitation, and palliative care for patients with advanced disease. The European Union provides a mature policy and clinical environment for cancer care quality, where guideline-based nutrition support, cross-border research collaboration, cancer rehabilitation, and patient-centered outcomes are increasingly relevant to cachexia management. BRICS countries represent a large and heterogeneous cancer patient population, with strong need for scalable cachexia screening, cost-effective nutritional interventions, oncology workforce development, and research that reflects varied tumor profiles, late presentation patterns, and care settings. The G7 shows high levels of oncology innovation, clinical research activity, digital health adoption, and supportive-care specialization, making it influential in defining evidence standards for cachexia endpoints, multimodal treatment protocols, and real-world evidence generation. NATO member countries, while primarily a geopolitical grouping, include many health systems with advanced oncology and rehabilitation capabilities, where cancer cachexia management is increasingly tied to healthcare infrastructure resilience, aging populations, integrated chronic disease care, and continuity of cancer services.

Key Country Insights Shaping Cancer Cachexia Management

The United States has a strong foundation in oncology research, supportive care, palliative medicine, cancer rehabilitation, and digital monitoring, positioning cancer cachexia as an important focus for improving treatment tolerance and patient-reported outcomes. Canada emphasizes equitable cancer care, nutrition services, and multidisciplinary oncology pathways, with increasing attention to functional status and quality of life in advanced cancer. Mexico faces growing demand for cancer cachexia recognition as oncology access expands and gastrointestinal, lung, breast, and other cancer care needs rise. Brazil is a major regional oncology hub where disparities between public and private care settings make standardized cachexia screening, nutritional support, and palliative care referral important. The United Kingdom benefits from established cancer networks, palliative care expertise, and clinical guidance that supports earlier identification of malnutrition, anorexia, and wasting. Germany has strong oncology infrastructure, rehabilitation medicine, nutritional care capability, and clinical research capacity that support structured cachexia management. France integrates nutrition, geriatric oncology, and supportive care into cancer services, strengthening attention to frailty, sarcopenia, and muscle loss. Russia's cancer care modernization efforts create opportunities to improve cachexia pathways, particularly in advanced and late-diagnosed cancers. Italy has significant clinical interest in nutrition, aging, and oncology rehabilitation, making cachexia care relevant across hospital and community settings. Spain's oncology system increasingly emphasizes survivorship, palliative care, and multidisciplinary treatment, supporting better management of anorexia, fatigue, and weight loss. China faces substantial cachexia-related need due to its large cancer population and high burden of lung, gastric, esophageal, liver, and colorectal cancers, while rapid hospital modernization and digital health adoption support broader screening potential. India's rising cancer burden, late presentation in many settings, and nutrition vulnerability make affordable cachexia assessment and multimodal supportive care highly important. Japan's aging population and advanced oncology system make sarcopenia, frailty, and cancer cachexia central to treatment planning and geriatric oncology. Australia combines guideline-based oncology, nutrition support, rehabilitation services, and regional telehealth capabilities, which can improve access to cachexia care across dispersed populations. South Korea's advanced cancer centers, strong diagnostic capacity, and technology-enabled healthcare environment support precision approaches to body composition assessment, symptom monitoring, and integrated cachexia management.

Actionable Recommendations for Cancer Cachexia Leaders

Industry leaders should prioritize earlier detection by embedding routine weight-loss screening, appetite evaluation, muscle function assessment, and body composition review into oncology workflows. Multimodal care models should be strengthened through collaboration among oncologists, dietitians, physiotherapists, nurses, palliative care specialists, pharmacists, and behavioral health professionals. Research strategies should focus on clinically meaningful endpoints, including functional performance, treatment adherence, fatigue, quality of life, lean body mass, inflammatory biomarkers, and patient-reported outcomes. Digital health developers should validate remote monitoring tools that capture nutrition intake, mobility, fatigue, and symptom burden without increasing patient workload. Healthcare providers should standardize referral triggers for nutrition and rehabilitation services, particularly for high-risk cancers and patients undergoing intensive systemic therapy. Policymakers and payers should support access to evidence-based nutrition counseling, symptom control, exercise rehabilitation, and palliative care as core components of cancer treatment. Organizations pursuing therapeutic innovation should design inclusive studies that reflect older adults, multimorbidity, diverse tumor types, variable nutritional status, and real-world oncology settings.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified clinical, scientific, and public health evidence related to cancer cachexia. The methodology includes review of peer-reviewed oncology and nutrition literature, clinical practice guidelines, consensus definitions, cancer registry perspectives, public health publications, regulatory science discussions, and evidence on supportive oncology, sarcopenia, palliative care, rehabilitation, and digital health. Insights are synthesized through thematic analysis across disease burden, clinical presentation, diagnostic practices, intervention models, technology adoption, regional health system variation, and emerging research directions. Particular emphasis is placed on evidence-backed clinical relevance rather than commercial estimation, including the role of cachexia in treatment tolerance, functional decline, quality of life, hospitalization, and survival-related outcomes. The analysis excludes market sizing, market share, and forecasting and focuses instead on healthcare implications, innovation priorities, and strategic considerations for stakeholders involved in cancer cachexia care.

Conclusion

Cancer cachexia is a high-impact oncology complication that requires earlier recognition, coordinated multidisciplinary care, and continued innovation in assessment and intervention. The field is advancing from reactive management of severe wasting toward proactive strategies that integrate nutrition, exercise, symptom control, inflammation-aware research, digital monitoring, and patient-centered outcomes. Regional and country-level differences in cancer burden, diagnostic timing, oncology infrastructure, and supportive-care access will shape how cachexia pathways are implemented globally. Artificial intelligence, imaging analytics, and remote monitoring can strengthen precision cancer cachexia care, but clinical validation, interoperability, and equitable deployment remain essential. For healthcare leaders, the central opportunity is to make cancer cachexia management a routine part of oncology quality improvement, ensuring that patients receive timely support to preserve function, improve treatment resilience, and maintain quality of life throughout the cancer care continuum.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Cachexia Market, by Therapy Type

• 7.1. Introduction
• 7.2. Pharmacological Interventions
  • 7.2.1. Progestogens
  • 7.2.2. Corticosteroids
  • 7.2.3. Nonsteroidal Anti-inflammatory Drugs
• 7.3. Combination Approaches
  • 7.3.1. Drug And Nutrition Combinations
  • 7.3.2. Multimodal Cachexia Management Programs
• 7.4. Nutritional Support

8. Cancer Cachexia Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intravenous
  • 8.2.2. Subcutaneous
• 8.3. Oral

9. Cancer Cachexia Market, by Age Group

• 9.1. Introduction
• 9.2. Adult
• 9.3. Geriatric
• 9.4. Pediatric

10. Cancer Cachexia Market, by Gender

• 10.1. Introduction
• 10.2. Male
• 10.3. Female

11. Cancer Cachexia Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Cancer Cachexia Market, by End User

• 12.1. Introduction
• 12.2. Ambulatory Care
• 12.3. Home Care
• 12.4. Hospitals

13. Cancer Cachexia Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Cancer Cachexia Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cancer Cachexia Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AAVogen Inc.
• 17.2. Actimed Therapeutics Ltd.
• 17.3. Aeterna Zentaris Inc.
• 17.4. Aphios Corporation
• 17.5. Artelo Biosciences Inc.
• 17.6. AVEO Pharmaceuticals Inc.
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Bristol-Myers Squibb Company
• 17.9. Fresenius Kabi AG
• 17.10. Green Cross Wellbeing Corporation
• 17.11. Helsinn Healthcare SA
• 17.12. INOVIO Pharmaceuticals Inc.
• 17.13. Mankind Pharma Ltd.
• 17.14. Merck & Co. Inc.
• 17.15. MetaFines Co., Ltd.
• 17.16. NeuBase Therapeutics, Inc.
• 17.17. NGM Biopharmaceuticals Inc.
• 17.18. Ono Pharmaceutical Co., Ltd.
• 17.19. Pfizer Inc.
• 17.20. Tetra Bio-Pharma